Abstract
Anti-PD-1 antibody monotherapy (PD1) leads to favorable responses in advanced cutaneous melanoma (CM) among Caucasian populations; however, recent studies have indicated limited efficacy in mucosal melanoma (MM) than in CM. Thus, advanced MM patients (pts) are candidates for anti-PD-1 plus anti-CTLA-4 combination therapy (PD1+CTLA4). Meanwhile, data on the efficacy of immunotherapy in MM are limited. We aimed to compare the efficacies of first-line PD1 and PD1+CTLA4 in Japanese advanced MM pts in the real-world setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
